


RESEARCH ARTICLE

Open Access



# A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa

Janan J. Dietrich<sup>1,2\*</sup> , Millicent Atujuna<sup>3†</sup>, Gugulethu Tshabalala<sup>1</sup>, Stefanie Hornschuh<sup>1</sup>, Mamakiri Mulaudzi<sup>1</sup>, Michelle Koh<sup>4</sup>, Nadia Ahmed<sup>3,5</sup>, Richard Muhumuza<sup>6,7</sup>, Andrew S. Ssemata<sup>6,7</sup>, Kennedy Otwombe<sup>1</sup>, Linda-Gail Bekker<sup>3</sup>, Janet Seeley<sup>6,7</sup>, Neil A. Martinson<sup>1</sup>, Fern Terris-Prestholt<sup>7</sup> and Julie Fox<sup>8</sup>

## Abstract

**Background:** The uptake and adherence of daily oral PrEP has been poor in high-risk populations in South Africa including young people. We used qualitative research methods to explore user preferences for daily and on-demand oral PrEP use among young South Africans, and to inform the identification of critical attributes and attribute-levels for quantitative analysis of user preferences, i.e. a discrete choice experiment (DCE).

**Methods:** Data were collected between September and November 2018 from eight group discussions and 20 in-depth interviews with young people 13 to 24 years in Cape Town and Johannesburg. Using a convenience sampling strategy, participants were stratified by sex and age. Interviewers used a semi-structured interview guide to discuss several attributes (dosing regimen, location, costs, side effects, and protection period) for PrEP access and use. Group discussions and in-depth interviews were audio-recorded, transcribed verbatim and translated to English. We used framework analysis to explore context-specific attributes and attribute-levels for delivering oral PrEP in South Africa. The adolescent community advisory board, expert and study team opinions were consulted for the final DCE attributes and levels.

(Continued on next page)

\* Correspondence: [dietrichj@phru.co.za](mailto:dietrichj@phru.co.za)

Janan Janine Dietrich and Millicent Atujuna are shared first authorship.

<sup>1</sup>Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

<sup>2</sup>Health Systems Research Unit, South African Medical Research Council, Bellville, South Africa

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

**Results:** We enrolled 74 participants who were 51% ( $n = 38/74$ ) male, had a median age of 18.5 [Interquartile range = 16–21.25] years, 91% ( $n = 67/74$ ) identified as heterosexual and 49% ( $n = 36/74$ ) had not completed 12th grade education. Using the qualitative data, we identified five candidate attributes including (1) dosing regimen, (2) location to get PrEP, (3) cost, (4) route of administration and (5) frequency. After discussions with experts and the study team, we revised the DCE to include the following five attributes and levels: dosing regime: daily, and on-demand PrEP; location: private pharmacy, public clinic, mobile clinic, ATM); cost: free-of-charge, R50 (~2GBP), R265 (~12GBP); side effects: nausea, headache, rash; and duration of protection: fulltime protection versus when PrEP is used).

**Conclusions:** There is limited literature on qualitative research methods describing the step-by-step process of developing a DCE for PrEP in adolescents, especially in resource-constrained countries. We provide the process followed for the DCE technique to understand user preferences for daily and on-demand oral PrEP among young people in South Africa.

**Keywords:** Discrete choice experiment (DCE), Conjoint analysis, HIV, Oral pre-exposure prophylaxis (PrEP), Preferences, Adolescents, Young people, South Africa

## Background

The prevention of Human Immunodeficiency Virus (HIV) in young people in South Africa remains a priority, firstly because it is a preventable chronic condition which would in turn negate the risk of associated physical and psychological co-morbidities, and secondly because of sustained high HIV prevalence and incidence among adolescents in both South Africa and sub-Saharan Africa (SSA). Moreover, interventions for HIV prevention within SSA have had limited effect, despite high levels of HIV awareness. The limited effect of HIV prevention interventions is largely attributable to poor adherence observed in major clinical trials [1–7].

Globally, pre-exposure prophylaxis (PrEP) shows efficacy in preventing HIV amongst males and females [8–10], with a daily PrEP regimen shown to be effective and associated with decreasing HIV incidence in heterosexual males and females, males who have sex with males (MSM), transgender females, and people who inject drugs (PWID) [2, 9, 11–13]. This regimen has subsequently been recommended by the World Health Organization (WHO) for individuals at high risk for infection [2]. On-demand PrEP, which consists of four pericoital doses, represents a potentially more cost-effective approach [14]. However, the on-demand regimen is not yet recommended for populations other than MSM due to the lack of studies and the complexity of the regimen [15].

Despite availability of PrEP in the public sector to females 15–24 years in South Africa [16] there is still a lack of awareness and uptake of PrEP among young South Africans [17]. The expansion of PrEP is urgently required across SSA, but can only be optimised by understanding barriers to PrEP uptake in young people. Currently, there is no model of PrEP provision for adolescent males who have been over-looked in HIV

prevention research [15] but contribute to HIV incident infections [18].

Discrete choice experiments (DCEs), also known as conjoint analysis, can direct researchers to user needs, and inform how to best formulate or implement a health intervention, as DCE allows researchers both to identify attributes [19] of an intervention that make it attractive and also to rank the importance of that attribute [20]. The results from DCEs are critical in predicting the success of different approaches to implementing particular healthcare interventions in relevant communities or populations [21, 22].

DCE-based studies on PrEP preferences in specific cohorts are lacking, including young people in Africa. Recently, Dubov et al. (2019) performed a DCE to inform efforts to improve PrEP access and uptake among MSM in the United States [23]. As for DCE-based studies on PrEP in the African context, Kuteesa et al. (2019) conducted a DCE-based study investigating fishing communities in Uganda [24], while Lancaster et al. (2019) examined preferences among female sex workers (FSWs) in Malawi [25]. There has also been an increased interest in using DCEs to explore stakeholder preferences for healthcare interventions and changes in policy, as well as using them to support the prioritization, design and implementation of healthcare interventions [20].

The Combined HIV Adolescent Prevention Study (CHAPS) aims to investigate the acceptability and feasibility of implementing daily and on-demand PrEP among adolescents in South Africa, Uganda and Zimbabwe and to determine an on-demand PrEP dosing schedule for insertive sex in young males [26]. As part of the social science component, we used qualitative research to develop DCE choice sets to identify attributes and attribute levels for PrEP delivery among young people in South Africa.

The DCE technique can be simplified into four components: survey design, piloting and administration to participants, data analysis, and implement interventions for the relevant populations, or design further experiments [20, 27]. In this paper we focus on the preliminary qualitative research conducted to design the DCE for survey administration.

Therefore, the aim of this paper is to describe qualitative research methods used to identify and develop the DCE choice sets and the salient attributes and preferences for PrEP delivery in young people aged 13–24 years in two South African cities.

## Methods

### Study design

A qualitative research approach was selected to form part of a broader rigorous DCE approach, wherein the qualitative research is good practice in the formative stage to develop and design the DCE [22]. Data collection from in-depth interviews (IDIs) allowed for individual perspectives while group discussions (GDs) provided data collection within the context of a larger group [28].

### Study setting

Data were collected from September to November 2018 at the Perinatal HIV Research Unit (PHRU) in Johannesburg and the Desmond Tutu HIV Centre (DTHC) in Cape Town. Participants were recruited in informal peri-urban communities established as residential areas for black South Africans during apartheid, characterized by overcrowding, unemployment, with limited resources and service delivery [29].

The PHRU is situated at the Chris Hani Baragwanath Academic Hospital in Soweto, has conducted research in HIV prevention, care and treatment for more than 20 years as well as providing healthcare services for the population of Soweto. Soweto is southwest of Johannesburg city in the province of Gauteng, and is estimated to have a population of ~2.5–3 million in an area of 63 km<sup>2</sup> [30]. The prevalence of HIV in the Gauteng province is 15.2% among 15–49 year olds [31]. The second site, the DTHC is located in the Klipfontein/Mitchells Plain sub-district, in the Southern part of the Cape Town Metro. Compared to other district municipalities within the Western Cape, the Cape Town Metro bears the highest population size and prevalence of HIV [31]. Both PHRU and DTHC have a well established Adolescent Community Advisory Boards (ACAB), who are deeply rooted in their respective communities.

### Initial literature review

A literature search was conducted to start the attribute development process using the terms in Discrete choice experiment (DCE), Sub-saharan Africa (SSA), South

Africa (SA), pre-exposure prophylaxis (PrEP), young people. The terms were used in a variety of combinations. While there has been a DCE-based study that included preferences concerning PrEP in South Africa [21], this study conducted in Johannesburg examined a variety of other HIV and pregnancy prevention methods along with PrEP, and focused only on female South Africans in diverse settings. For our study, based on literature, important attributes for delivering PrEP to young people included the cost of PrEP, the location of PrEP dispensaries, and dosage frequency.

### Procedures of the qualitative study for developing the DCE

As part of the larger CHAPS study, qualitative data were collected between September to November 2018 through eight group discussions (GDs) and 20 in-depth interviews (IDIs) with young people aged 13 to 24 years; four GDs and 10 IDIs in Cape Town and Johannesburg, respectively. In total, 54 participants took part in GDs; 28 in Johannesburg and 26 in Cape Town and a total of 20 participated in IDIs.

### Study population, sampling and recruitment process

Fieldworkers used a convenience sampling strategy to recruit eligible males and females 13–24 years, who were HIV negative on a rapid HIV test (Soweto used the ABON HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device and Cape Town used the Alere Determine test) and reported sexual activity in the past 3 months. Most participants in our study had moderate to no prior knowledge about PrEP. In Soweto, participants for IDIs and GDs were actively recruited through community organisations, taxi ranks and outside premises of public meeting places such as shopping malls and community parks. In Cape Town, participants were recruited through local schools, shopping malls, the library, word of mouth referrals and walk in at the research clinic.

### Data collection procedures

IDIs and GDs were stratified by age (13–17 years and 18–24 years) and sex (males and females) for Soweto but not for Cape Town. GDs included mixed sex and age groups in Cape Town. Prior to the interviews, participants completed a short five-minute socio-demographic questionnaire [Additional File 1]. GDs and IDIs were facilitated by experienced and trained researchers fluent in English and local languages used (e.g. IsiZulu, IsiSesotho and IsiXhosa). They were conducted in secure and private locations at both sites. During the GDs, two researchers were present, one served as the main facilitator and the other as a note taker and co-facilitator. A semi-structured guide including open ended questions and

relevant probes was used to facilitate and guide the discussions during the IDIs and GDs [Additional File 2]. Participants were allocated a participant identification number, which was used while completing the demographic questionnaire and during the GDs and IDIs. Participants used pseudonyms during all discussions to maintain anonymity. The IDIs and GDs lasted 36 min on and 100 min on average, respectively. All IDIs and GDs were audio-recorded, transcribed verbatim, and later translated to English.

### Measures

The brief socio-demographic questionnaire included questions on sex, age, race, primary home language, sexual orientation, and education level.

Trained qualitative researchers used a semi-structured interview guide to conduct the GDs and IDIs. The guide covered topics to identify several attributes for PrEP access and use, including: choice of dosing regimen (i.e. daily versus on-demand PrEP), alternative routes of PrEP administration (i.e. implant and injection), dispensing location (pharmacy, clinic, adolescent/youth centre, doctors office), and time to be spent in obtaining PrEP.

### Ethical approval

This study was approved by the Human Research Ethics Committees of the University of the Witwatersrand and University of Cape Town. Written study informed consent or assent was obtained from all participants. In Soweto, parents/ legal guardians provided written informed consent for participants younger than 18 years. Participants and parent/legal guardian signed separate forms for audio-recording. Cape Town had a parental waiver and did not require parental consent for participants under 13–17 years. Therefore, for Cape Town, participants provided written consent regardless of age. Participants were reimbursed R100 (~ 5GBP) in Johannesburg and R120 (~6GBP) in Cape Town respectively for their study participation.

### Data analysis

#### *Qualitative data analysis*

Framework analysis, a data analysis approach relevant for applied research, was used to analyse the data [32]. Framework analysis provides a highly systematic method of categorizing and organizing data according to key themes, concepts and emergent categories in grids or matrices. Transcripts were coded to identify context-specific attributes and attribute-levels for delivering oral PrEP in South Africa. Initial coding was conducted by two trained qualitative research team members at each site. Initially, the researchers read through four transcripts (two GDs and two IDIs) to gain an understanding of the data to develop an Excel spreadsheet codebook.

Each transcript was then individually coded using a line by line technique to assign codes to text. A second analyst also coded the same transcripts using the line by line technique to identify codes. Both analysts then met to discuss codes identified and differences were discussed. If there was a disagreement among codes, this was discussed until a common agreement was reached. Codes were then categorized into themes and sub-themes by both researchers. Themes identified were captured on an Excel spreadsheet and a comprehensive codebook was developed. The codebook was shared with the rest of the team from both sites for final review and input. In order to ensure data trustworthiness, analysis was conducted in a consistent manner: we used the same codebook across all sites, and conducted frequent comparison on code use through discussion across sites. The main analyst for this paper reviewed transcripts and coding for all sites to ensure that the coding was indeed aligned with transcripts.

#### *Quantitative data analysis*

Descriptive statistics and frequencies were used to analyse socio-demographic characteristics using Statistical Package for Social Sciences (SPSS) Version 25.0 [33].

### Results

Participant characteristics.

The median age of participants was 18.5 years (inter-quartile range [IQR = 16–21.25]), 51% ( $n = 38/74$ ) were male, 91% ( $n = 67/74$ ) of participants identified as heterosexual, all were Black Africans ( $n = 74/74$ , 100%), and 49% ( $n = 36/74$ ) had not completed 12th grade education.

#### **Qualitative results to identify and develop attributes and attribute-levels**

Table 1 illustrates the full list of all attributes and attribute-levels, which were identified in consensus among the two qualitative research analysts. Initially, eight candidate attributes with respective attribute levels were identified including (1) Frequency of administration, (2) side effects, (3) cost, (4) location of PrEP dissemination, (5) person responsible for dispensing, (6) duration of PrEP use, (7) pill intake, and (8) alternative routes of administration. Attributes and attribute-levels were identified from the transcripts and prominent participants' quotes were directly extracted to illustrate each attribute and attribute-level (Table 1).

#### *Frequency of administration*

The majority preferred a daily PrEP dosing regimen over an on-demand PrEP dosing regimen, citing unplanned sexual intercourse as one of the main reasons. Substance

**Table 1** List of DCE Attributes

Attribute label	Lay terminology	Key quotations from qualitative data	Labels of plausible levels	Frequency	Final inclusion
Frequency of administration	How often one can take PrEP	"I prefer taking it [PrEP] daily because as I have said we do not plan to have sex so if I take it daily even if there is a certain day which chooses to come up for me to have sex I would know that I have taken the PrEP medication and I would know that I have protected myself even more now because I will not take an advantage of it"(IDI, Male,18–24 years, Soweto)	Daily	20	YES
		"I: And then you were saying that you would like to take PrEP when you are going to have sex? R: Yes. I: But then for how long now? R: For how long? I may maybe say I would take it [PrEP] 5 days before. If I know that on that weekend I am going to be seen by my partner. (IDI, Male, 13–17 years, Cape Town)	On demand	9	
Side Effects	Negative reaction to medication	"Sometimes you know when we vomit you get confused, you don't know whether are you sick or you nauseous." (IDI, Female,18–24 years, Soweto)	Nausea	7	YES
		"I occasionally had headaches" (IDI, Female, 18–24 years, Cape Town)	Headache	5	
		"I think that if there is a problem, it will help to show that there is a problem somewhere, you might get a rash and you might think that you have an allergy" (GD, Females,18–24 years, Soweto)	Rash	3	
Cost	How much to pay for PrEP	"I agree with those who said we get it [PrEP] for free, some families are struggling financially and I live with my grandmother which means that from my granny's money I have to get money for PrEP?" (GD, Females, 18–24 years, Soweto)	Free	6	YES
		"R: R50. I: Okay you would buy it [PrEP] for R50 [confirms]. I: And then how long would it [PrEP] last you? R: A month." (IDI, Females, 18–24 years, Cape Town)	ZAR10–150 (~ 50 penny – 7GBP)	22	
		"Maybe it [PrEP] could be, maybe 10 pills could be R250." (IDI, Female, 13–17 years, Soweto)	ZAR200–300 (~9–14 GBP)	3	
Location of dissemination	Where to get PrEP	"It will be easy for me to get it [PrEP] from the clinic because I don't have money, I don't have money to buy it, so that's why I am saying the clinic. It will be easy for me to get it [PrEP] from the clinic." (GD, Males,13–17 years, Soweto)	Clinic	25	YES
		"I would like to have it [PrEP] if available at the pharmacy and be sold there, like Shoprite [local low-cost store]. At Shoprite pharmacy no one will see you when you go there and no one knows you so you will just buy it." (GD, Male and Female, 15–23 years, Cape Town)	Pharmacy	14	
Person responsible for dispensing PrEP	Who to give out PrEP	"Doctors who are treating HIV because they won't just give you the pills, they will even explain why you must use something like that and how you must use it [PrEP]. (IDI, Male,13–17 years, Soweto)	Doctor	15	NO
		"A nurse, a female, but like around our age even if it's 30, you see but someone who understands. (GD, Males and Females, 17–22 years, Cape Town)	Nurse	8	
		"I would prefer them [HIV counselors] because they are educated to counsel you first and make sure you are okay before you take something you don't know. Nurses can explain but they don't explain as well as a counsellor. A counsellor listens to you and you both listen to each other whereas a nurse just tells you what to do and they don't even want to know about your concerns" (GD, Female, 18–24 years, Soweto)	HIV counselor	6	
Duration of PrEP use	Length of time to take PrEP	"So knowing that you taking PrEP for the rest of your life you're safe you don't have to worry about anything." (IDI, Female, 18–24 years, Soweto)	Lifetime	11	NO
		"I would take it [PrEP] 5 days before ... If I know that on that weekend I am going to be seen by my partner."(IDI, Male,13–17 years, Cape Town)	Five days before sex	1	
		"It should be ten years just like the loop so that we can see how well people take to it [PrEP]. Like this thing that they put in your arm [refers to implant]" (GD, Females,18–24 years, Soweto)	Ten years	2	

**Table 1** List of DCE Attributes (Continued)

Attribute label	Lay terminology	Key quotations from qualitative data	Labels of plausible levels	Frequency	Final inclusion
Pill intake	Number of desired pills to take	"I: So how many pills a day do you think a person should take? R: One a day. I: Ok one right why do you think so? R: No people will get bored in taking two or three pills. (IDI, Female, 13–17 years, Cape Town)	One pill	13	NO
		"R: Maybe two. I: Two. R: Yes, in the morning and at night.(IDI, Male, 13–17 years, Soweto)	Two pills	8	
Alternative routes of administration	Method of PrEP administration	"P: Implant. I: Why? P: you do not have to go to the clinic if it is free. You don't have to go to the clinic every time to get it" (IDI, Female, 18–24 years, Soweto)	Implant	6	NO
		"Since I am a forgetful person, I wish PrEP can be injectable just like contraception" (GD, Males and Females, 15–23 years, Cape Town)	Injection	20	

use was also identified as a factor that leads to unplanned sex.

*"The reason is because you don't choose when you will have sex just like Esihle [pseudonym] mentioned that things such as Nandos, drugs and alcohol and the next thing you are kissing leading to sex." (GD, Females, 18–24 years, Soweto)*

*"Because I don't know when I'm going to have sex. I don't plan to have sex it just happens." (IDI, Female, 13–17 years, Cape Town)*

There were however some participants who preferred to take PrEP on demand stating that they might not remember to take a pill daily and and that it would be easier to take PrEP only when they know that they were going to engage in sexual intercourse.

*"I don't see the reason why I should take it [PrEP] when I know I am not going to have sex, I am not going to be at risk." (IDI, Male, 13–17 years, Cape Town)*

*"How am I going to remember to take the pill so I would rather take it [PrEP] as an on demand." (GD, Females, 18–24 years, Soweto)*

#### Side effects

Some participants spoke of side effects from personal experience and some from information shared by people using PrEP. Participants stated multiple side effects, including, headaches, fatigue and "sleepiness", that could be experienced when taking PrEP. They expressed that some side effects might only be experienced for a short period, such as nausea, vomiting, stomach aches and diarrhea, especially when the body is not used to the drug.

*"When you have just started maybe when you are not used to it [PrEP], maybe it can make you vomit but as you keep getting used to it, your body will get used to the idea that you are always taking tablets." (GD, Females, 13–17 years, Soweto)*

*"For me, I heard that when you start something it has side effects, right? Other people said that this PrEP thing that you're eating causes diarrhea, you see? Others become thin, others grow spots [a rash]." (GD, Males and Females, 13–20 years, Cape Town)*

Other potential side effects that participants felt could result from taking PrEP included changes of the skin, body weight, or developing a rash.

*"Side effects like if you take PrEP maybe you can gain weight. Or maybe you lose weight, do you see? Or maybe [change] complexion maybe it causes pimples." (IDI, Male, 13–17 years, Cape Town)*

*"You might get a rash and you might think that you have an allergy." (GD, Females, 18–24 years, Soweto)*

#### Cost of PrEP

The pricing of PrEP was based on GD and IDI participants' suggestions. The actual cost of a months supply of daily generic Truvada (tenofovir-disoproxil and emtricitabine) as PrEP, as approximately R200 (~ 9GBP), was also taken into consideration when contextualizing the attribute-levels for the cost of PrEP. Some participants preferred PrEP to be free, while others expressed they would willing to pay. A few participants reported that they would not be able to access PrEP if there was a price attached to it due to a low socio-economic status. To buy PrEP would mean choosing between buying basic essential goods versus PrEP.

*"I agree with those who said we get it [PrEP] for free, some families are struggling financially and I live with my grandmother which means that from my granny's money I have to get money for PrEP?" (GD, Females, 18–24 years, Soweto)*

*"I would prefer to get it [PrEP] for free." (IDI, Male, 13–17 years, Cape Town)*

Participants suggested various prices of PrEP, ranging from R10 (50 cents) to a maximum of R300 (14GBP). The varying prices were also justified with the number of tablets that one person could afford and were also based on a monthly supply. Overall, participants stated it would be beneficial for them to be able to access PrEP to protect themselves against HIV, even when there is a cost attached to accessing PrEP.

*"P: I would be willing to even if okay for us especially in the hood [neighbourhood] there it could cost maybe R20 each I would meet means and hustle hard for them so that I know I am on a safe side. I: So R20 for a bottle? P: Each pill I: R20 for one pill." (IDI, Male, 18–24 years, Soweto)*

*"R: R50. I: Okay you would buy it [PrEP] for R50 [confirms]. R: Uhm. I: And then how long would it [PrEP] last you? R: A month." (IDI, Female, 18–24 years, Cape Town)*

#### **Location of PrEP dissemination**

It was important to get an understanding on where participants would like to access PrEP. Since services are free at the local clinics this is where some participants opted to access PrEP.

*"It will be easy for me to get it [PrEP] from the clinic because I don't have money..., I don't have money to buy it [PrEP], so that's why I am saying the clinic. It will be easy for me to get it [PrEP] from the clinic." (GD, Males, 13–17 years, Soweto)*

*"I would wish to get it [PrEP] from the clinic. Yes, a public clinic because at the clinic you are given pills, it is not known what these are for. They are handed out...when you go looking for a PrEP pill, you should receive it in a place for pills [pharmacy]." (IDI, Female, 18–24 years, Cape Town)*

Other participants opted for pharmacies, as they stated it was more private and confidential compared with a

local clinic. Participants also stated that accessing PrEP through a pharmacy would be faster without long queues.

*"I would like to have it [PrEP] available at the pharmacy and be sold there. No one will see you when you go there {pharmacy} and no one knows you so you will just buy it [PrEP]." (GD, Males and Females, 15–23 years, Cape Town)*

#### **Person responsible for dispensing PrEP**

Participants stated that doctors, nurses and HIV counsellors would be best suited to dispense PrEP, because they were regarded as experienced and trained in testing and treating HIV, as well as being knowledgeable about prescribing and explaining PrEP to young people. However, some participants preferred a younger over an older health care provider to dispense PrEP.

*"I would prefer them [HIV counselors] because they are educated to counsel you first and make sure you are okay before you take something you don't know. Nurses can explain but they don't explain as well as a counsellor. A counsellor listens to you and you both listen to each other whereas a nurse just tells you what to do and they don't even want to know about your concerns." (GD, Females, 18–24 years, Soweto)*

*"A person for young people who is able to reach out to young people, someone friendly. So it may happen that she handles such department. She has to be young person so that we girls are able to talk to her and boys can have a male to talk to." (GD, Males and Females, 15–23 years, Cape Town)*

#### **PrEP dosing**

Participants discussed different dosing periods for taking PrEP. These differed from the timeframe to take PrEP to be protected for the next sexual intercourse, to the time period PrEP should be taken once started on it.

*"I would prefer if they take it [PrEP] once a day but for a lifetime." (IDI, Male, 18–24 years, Soweto)*

*"I may maybe say I would take it [PrEP] five days before [sex]. If I know that on that weekend I am going to be seen by my partner, something like that." (IDI, Male, 13–17 years, Cape Town)*

*“It [PrEP] should be ten years just like the loop so that we can see how well people take to it. Like this thing that they put in your arm.” (GD, Females, 18–24 years, Soweto)*

#### **Pill intake**

Overall, participants stated that they would be willing to take one pill or two pills per dose. However, the majority preferred to only take one pill, especially when taking it over a longer period of time. If taking two pills, participants would prefer to take one in the morning and the other in the evening.

*“One a day...people will get bored in taking two or three pills.” (IDI, Female, 13–17 years, Cape Town)*

*“It is easy to take one pill because if you take more than 1 pill the more you get discouraged to take it because you will be like so many pills why? Why do I have to take pills 3 times a day.” (IDI, Female, 18–24 years, Soweto)*

#### **Alternative route of administration**

During the GDs and IDIs, alternative routes of administration were discussed. Participants reported they would choose an implant or injectable as it would only need to be administered once and would not require returning to the clinic as frequently compared to using oral PrEP.

*“Since I am a forgetful person, I wish PrEP can be injectable just like contraception.” (GD, Males and Females, 15–23 years, Cape Town)*

*“Implant because injection people are scared of pain whenever we talking about injection comes pain in our heads but implant it is something which you do once off maybe then it last for a certain period which is intended for it to last.” (IDI, Male, 18–24 years, Soweto)*

#### **Expert opinion**

The study team consulted two experts experienced in designing and implementing DCEs in South Africa. Through an iterative process of discussions with these experts four of the initial eight candidate attributes were retained with three attribute-levels, each, except for the dosing regimen attribute, which consisted of two attribute-levels, daily and on-demand PrEP. Table 1 indicates whether the attribute identified during the qualitative analysis process was retained after the discussion phase with the experts (last column). The discussion was aimed at selecting the most relevant attributes with a

maximum of three attribute-levels each. This was also important to ensure the DCE incorporates a manageable number of attributes and level options to ensure that participants were not overwhelmed with the number of choice sets within the DCE. Consultation with other local team members ensured the language used for the attributes and attribute-levels was understandable and relevant within the South African context. For the location of PrEP dissemination it was deemed relevant to include a third attribute level, mobile clinic, as this has been a feasible approach to provide integrated health care, counselling services and dispensing of medication in underserved communities in Cape Town [34]. The final attributes and attribute-levels for the DCE included: dosing (daily and on-demand PrEP), location (private pharmacy, public clinic, mobile clinic), cost (free-of-charge, ZAR50 (~2GBP), ZAR200 (~9GBP)), and (4) side effects (nausea, headache, rash). After the iterative revision process, SAS was used to develop a statistically efficient and balances fractional factorial design of the DCE. Using SAS Enterprise Guide 7.15 (SAS Institute Inc., Cary, NC, USA) and the attributes identified in the qualitative study, the maximum possible number of attribute combinations was  $2^3 \times 3^1$  [35]. A smaller factorial design was further developed using the D-Efficiency criteria reducing the choice sets to a feasible number of 6. The final DCE was constructed with a total of six binary choice sets with two scenario descriptions and graphics of the attribute-levels and participants can choose between Choice A and Choice B (Fig. 1).

Permission was granted from the iPrevent study team to utilize illustrations for public community health clinic and private pharmacy as part of our DCE choice sets [36]. For the other illustrations the following sources are acknowledged: Daily PrEP [37]; on-demand PrEP [38]; cost illustrations [39, 40]; nausea [39]; headache [41]; rash [42].


#### **Pilot testing of the DCE with community advisory board members**

To ensure a community engaged approach to the DCE development, the ACAB of the PHRU ratified the DCE choice sets as developmentally and contextually appropriate [20]. ACAB members regarded the number of choice sets as manageable, easy to understand, user-friendly and easy to follow. In addition, ACAB members agreed the illustrating graphics included in the DCE choice sets were complementary, relevant and context-specific for the attributes and related levels.

#### **Discussion**

We explored PrEP delivery preferences among young people from a peri-urban setting in a multisite context in South Africa to develop a DCE. There are few





methodological literature that describes the process to systematically infer attributes and its levels for a DCE, which is considered an important technique to better understand and provide guidance on user preferences for interventions and products [20, 22]. Previous research in South Africa and SSA that used a DCE focused on hypothetical HIV prevention methods [43], HIV testing, HIV and family planning services [21]. One multinational study conducted in seven countries among key user groups aged 16 - ≥41 years to elicited acceptability of PrEP and factors to determine uptake [44].

Even though DCEs are increasingly used in the field of sexual and reproductive health, there is limited research on young people’s PrEP preferences in developing countries. Young people are considered a high risk group of acquiring HIV infection and important beneficiaries in accessing PrEP, yet oral PrEP uptake is low amongst South African youth [17]. Amongst a sample of 772 young people aged 16–24 years in the Eastern Cape, South Africa, only 1.7% had used PrEP [17]. Once young people initiate on PrEP, a substantial proportion do not persist with it [45]. Our documentation of the DCE methodology provided a unique opportunity for targeted investigation on how to best implement PrEP amongst this population to support uptake in resource-limited settings.

During the qualitative interviews, young people expressed an initial preference for daily over on-demand PrEP. Participants stated that the use of daily PrEP would ensure protection for spontaneous or unanticipated sexual activities. Previous research shows that young people are often less likely to anticipate sex, which also includes communication and control within relationships [25]. This may be particularly true for young females, as they often have less decision making power and be less likely able to negotiate when sex occurs [46]. This might impact on choosing daily versus on-demand PrEP. In addition, young people are at high risk of non-adherence to medications, including contraception, ART or other chronic medications [47]. While it may be more difficult for young people adhering to a strict fixed pre-intercourse and/or post-intercourse PrEP dosing regimen, it may also impact on optimal adherence to a daily PrEP regimen.

Participants in our study discussed the tradeoffs between locations to access PrEP with costs and confidentiality. Participants opted for accessing PrEP at their local clinics, mainly because services would be free. Others preferred to access PrEP at a pharmacy, for ease of access, privacy and confidentiality. Stigma and discrimination are commonly known barriers to accessing public health care facilities and lead for young people to

less likely engage in sexual and reproductive health care, including HIV services [48, 49]. Therefore, alternative locations for accessing PrEP might promote PrEP uptake among young people and support privacy and confidentiality, which was an important aspect for young people in our sample when getting PrEP. During a South African based demonstration project amongst females, PrEP initiation was high in youth-orientated, family planning and mobile outreach clinics [45]. Offering PrEP at different types of locations could be a suitable delivery model for young people. This may mitigate additional barriers, such as transportation, long distance to dispensing sites, and healthcare provider attitudes [50, 51]. In the South African setting, an integrated reproductive health care delivery model to access PrEP is feasible amongst females [45].

Participants in our study discussed their willingness to use alternative modalities for PrEP administration including injectables and implants. Current research is underway that tests the effectiveness of long-acting injectable formulations and intra-vaginal rings and potential alternatives to oral PrEP [52]. Further evaluations are required that focus on the willingness and perceptions of alternative application methods of PrEP amongst young people and not just for adults [53].

To better ensure that the final DCE was reflective of youth preferences we were able to incorporate a community engaged approach. The ACABs were actively involved in reviewing the choice sets for content, language, graphics and layout. This phase afforded the research team the opportunity to test the DCE choice sets supported response efficiency and content validity within the DCE [54, 55]. A youth engaged approach has been shown to work well in other settings, such as interventions for mental health, substance use and HIV prevention interventions [56, 57].

Next steps are to deliver the final DCE in a larger CHAPS survey and then to assess the preferences of young people for PrEP delivery in two South African cities, Soweto and Cape Town. It is anticipated that the results will provide important insights on how to align the implementation of PrEP to be most accessible and beneficial for young people, who present a key population in the HIV prevention response.

### Limitations

A few participants had prior PrEP experience, but the larger sample had limited to no prior exposure to PrEP. To avoid a potential bias based on those with PrEP experience, we included recruitment to locations outside of the clinic setting. Many participants that discussed topics related to PrEP access and use, drew from experience with other medication or from reports of others who took PrEP or where exposed to PrEP before. This

was particularly true when they discussed the location to access PrEP and possible side effects. Limited prior knowledge on PrEP might have influenced participant's responses. However, this was largely mitigated by the fact that discussions during the phase with experts confirmed the relevancy of the attributes and attribute-level identified during the qualitative interview phase.

At present, there is more biological evidence to support on-demand PrEP in males who have sex with males and less evidence to support such dosing options in females [58]. This qualitative research was conducted to explore participant preferences when provided with the choice for on-demand versus daily PrEP without explicitly stating that there was insufficient evidence for on-demand dosing in females. Previous research in adolescents showed a preference for using PrEP at periods of higher risk [59] – providing the impetus to better understand what it is that young people want. Therefore, our approach was to explore what ideal youth preferences were despite the biological evidence. Future research could explore how responses among young people would differ based on this biological limitation.

### Conclusions

There are few qualitative research methods studies describing the step-by-step process of developing a DCE for PrEP in adolescents, especially in resource-constrained countries. Using a systematic and robust approach, we use a developed and designed a DCE with attributes and levels for PrEP uptake that can be tested in young people in SA. We provide the process followed for the DCE technique to understand user preferences for daily and on-demand oral PrEP among young people in South Africa.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12913-020-05942-8>.

**Additional file 1.** Demographic Questionnaire. The brief socio-demographic questionnaire included questions on sex, age, race, primary home language, sexual orientation, and education level.

**Additional file 2.** Qualitative Interview Guide for Group Discussions and In-Depth Interviews. A semi-structured guide including open ended questions and relevant probes to facilitate and guide the discussions during Group Discussions and In-Depth Interviews.

### Abbreviations

ACAB: Adolescent Community Advisory Board; CHAPS: The Combined HIV Adolescent Prevention Study; DCE: Discrete Choice Experiment; DTHC: Desmond Tutu HIV Centre; FSW: Female sex worker; GDs: Group Discussions; HIV: Human Immunodeficiency Virus; IDIs: In-depth Interviews; IQR: Interquartile Range; MSM: Males who have sex with males; PHRU: Perinatal HIV Research Unit; PrEP: Pre-Exposure Prophylaxis; PWID: People who inject drugs; SA: South Africa; SPSS: Statistical Package for Social Sciences; SSA: sub-Saharan Africa; WHO: World Health Organization

**Acknowledgments**

We are particularly grateful to all the study participants (and parents) for the time and information they shared with us.

**Authors' contributions**

JJD, LGB, NAM, JF conceived the study. JJD, MA, SH designed the manuscript. SH, GT, MM participated in data collection and data analysis. JS provided oversight for the framework analysis approach. JJD, GT, SH, MM, NA, JS contributed to data interpretation. FTP provided overall expertise for the DCE approach. KO conducted the statistical data analysis to construct the final DCE choice sets. MK conducted the literature review. RM, AS, JF contributed to manuscript writing. JJD and MA interpreted and wrote the original manuscript draft. All authors revised and approved the final version of the paper.

**Funding**

This study is part of the EDCTP2 programme supported by the European Union (grant number RIA2016MC-1616 CHAPS). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. The work reported herein for JJD was made possible through funding by the South African Medical Research Council (SAMRC) through its Division of Research Capacity Development under the SAMRC Postdoctoral Programme (from funding received from the South African National Treasury) as well as the CIPHER GROWING THE LEADERS OF TOMORROW grant from the International AIDS Society (IAS). SH was supported by Consortium for Advanced Research Training in Africa (CARTA), which is funded by the Carnegie Corporation of New York (Grant No-B 8606.R02), Sida (Grant No:54100029), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The content hereof is the sole responsibility of the authors and do not necessarily represent the official views of the EDCTP, SAMRC, IAS or the other named funders.

**Availability of data and materials**

The qualitative datasets generated and/or analysed during the current study are not publicly available to maintain participant privacy and confidentiality, but are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Human Research Ethics Committees of the University of the Witwatersrand and University of Cape Town. Written study informed consent or assent was obtained from all participants. In Soweto, parents/legal guardians provided written informed consent for participants younger than 18 years. Participants and parent/legal guardian signed separate forms for audio-recording. For the Cape Town site, their institutional review board approved a parental waiver and did not require parental consent for participants 13–17 years. Therefore, for Cape Town, participants provided written consent regardless of age.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

<sup>1</sup>Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. <sup>2</sup>Health Systems Research Unit, South African Medical Research Council, Bellville, South Africa. <sup>3</sup>Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. <sup>4</sup>Harvard Global Health Institute, Harvard University, Cambridge, MA, USA. <sup>5</sup>Mortimer Market Centre, Central North West London NHS Trust, Off Caper Street, London WC1E 6 JB, UK. <sup>6</sup>Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda. <sup>7</sup>Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK. <sup>8</sup>King's College London, London, UK.

Received: 6 July 2020 Accepted: 19 November 2020

Published online: 06 January 2021

**References**

- Nicol MR, Adams JL, Kashuba AD. HIV PrEP trials: the road to success. *Clin Investigation*. 2013;3(3). <https://doi.org/10.4155/cli.12.155>.
- Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399–410. <https://doi.org/10.1056/NEJMoa1108524>.
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med*. 2016;375(9):830–9.
- Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town trial): a randomised, open-label, phase 2 trial. *The Lancet HIV*. 2018;5(2):e68–78. [https://doi.org/10.1016/s2352-3018\(17\)30156-x](https://doi.org/10.1016/s2352-3018(17)30156-x).
- Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2015;372(6):509–18. <https://doi.org/10.1056/NEJMoa1402269>.
- Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411–22. <https://doi.org/10.1056/NEJMoa1202614>.
- Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science (New York, NY)*. 2010;329(5996):1168–74. <https://doi.org/10.1126/science.1193748>.
- UNAIDS. Getting to Zero: HIV in Eastern and Southern Africa. Johannesburg, South Africa: UNAIDS; 2013. Accessed.
- McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet (London, England)*. 2016;387(10013):53–60. [https://doi.org/10.1016/s0140-6736\(15\)00056-2](https://doi.org/10.1016/s0140-6736(15)00056-2).
- Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. *AIDS (London, England)*. 2013;27(13):2155–60. <https://doi.org/10.1097/QAD.0b013e3283629037>.
- Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012;367(5):423–34. <https://doi.org/10.1056/NEJMoa1110711>.
- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587–99. <https://doi.org/10.1056/NEJMoa1011205>.
- Choopanya K, Martin M, Suntharasamaj P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet (London, England)*. 2013;381(9883):2083–90. [https://doi.org/10.1016/s0140-6736\(13\)61127-7](https://doi.org/10.1016/s0140-6736(13)61127-7).
- WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: WHO; 2015. <https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/>. Accessed 02 June 2020.
- Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand Preexposure prophylaxis in men at high risk for HIV-1 infection. *N Engl J Med*. 2015;373(23):2237–46. <https://doi.org/10.1056/NEJMoa1506273>.
- National Department of Health. PrEP Implementation Pack: South Africa 2016–2017. Pretoria, South Africa: NDoH; 2019. [https://www.prepwatch.org/wp-content/uploads/2017/07/SA\\_ImplementationPack.pdf](https://www.prepwatch.org/wp-content/uploads/2017/07/SA_ImplementationPack.pdf). Accessed 02 June 2020.
- Ajayi AI, Mudefi E, Yusuf MS, Adeniyi OV, Rala N, Goon DT. Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. *Medicine*. 2019;98(43):e17716. <https://doi.org/10.1097/md.00000000000017716>.
- UNAIDS. A snapshot of men and HIV in South Africa. UNAIDS: Geneva, Switzerland; 2017. <https://www.unaids.org/en/regionscountries/countries/southafrica>. Accessed 02 June 2020.

19. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. *Quality in health care* : QHC. 2001; 10(Suppl 1(Suppl 1)):i55–60. <https://doi.org/10.1136/qhc.0100055>.
20. Abiio GA, Leppert G, Mbera GB, Robyn PJ, De Allegri M. Developing attributes and attribute-levels for a discrete choice experiment on micro health insurance in rural Malawi. *BMC Health Serv Res*. 2014;14:235. <https://doi.org/10.1186/1472-6963-14-235>.
21. Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. *Med Decision Making*. 2018;38(1):120–33. <https://doi.org/10.1177/0272989x17729376>.
22. Coast J, Horrocks S. Developing attributes and levels for discrete choice experiments using qualitative methods. *J Health Serv Res Policy*. 2007;12(1): 25–30. <https://doi.org/10.1258/13558190779497602>.
23. Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. *AIDS Care*. 2019;31(5):545–53. <https://doi.org/10.1080/09540121.2018.1557590>.
24. Kuteesa MO, Weiss HA, Aabaasa A, Nash S, Nsubuga RN, Newton R, et al. Feasibility of conducting HIV combination prevention interventions in fishing communities in Uganda: a pilot cluster randomised trial. *PLoS One*. 2019;14(3):e0210719. <https://doi.org/10.1371/journal.pone.0210719>.
25. Lancaster KE, Lungu T, Bula A, Shea JM, Shoben A, Hosseinipour MC, et al. Preferences for pre-exposure prophylaxis service delivery among female sex workers in Malawi: a discrete choice experiment. *AIDS Behav*. 2020;24(5): 1294–303. <https://doi.org/10.1007/s10461-019-02705-3>.
26. Nash S, Dietrich J, Ssemata AS, Herrera C, O'Hagan K, Else L, et al. Combined HIV adolescent prevention study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. *Trials*. 2020;21(1):900. <https://doi.org/10.1186/s13063-020-04760-x>.
27. Adams J, Bateman B, Becker F, Cresswell T, Flynn D, McNaughton R, et al. Effectiveness and acceptability of parental financial incentives and quasi-mandatory schemes for increasing uptake of vaccinations in preschool children: systematic review, qualitative study and discrete choice experiment. *Health Technol Assessment (Winchester, England)*. 2015;19(94): 1–176. <https://doi.org/10.3310/hta19940>.
28. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. *Int J STD AIDS*. 2011;22(5):256–62. <https://doi.org/10.1258/ijsa.2009.009255>.
29. Smith DM. *The apartheid city and beyond: urbanization and social change in South Africa*: Routledge; 2003.
30. Statistics South Africa. Mid-year population estimates. Pretoria, South Africa. 2019. <https://www.statssa.gov.za/publications/P0302/P03022019.pdf>. Accessed 02 June 2020.
31. Simbayi LC, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African national HIV prevalence, incidence, behaviour and communication survey, 2017. Cape Town, South Africa: HSRP Press; 2019. [http://www.hsrc.ac.za/en/departments/saph/HAST\\_National\\_HIV\\_Survey](http://www.hsrc.ac.za/en/departments/saph/HAST_National_HIV_Survey). Accessed 05 June 2020.
32. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol*. 2013;13:117. <https://doi.org/10.1186/1471-2288-13-117>.
33. IBM Corp. *IBM SPSS Statistics for Windows*. Armonk, NY: IBM Corp; 2017. <https://hadoop.apache.org>. Accessed 17th June 2020.
34. Desmond Tutu HIV Foundation. *Mobile Services*. 2019. <https://desmondtutuhivfoundation.org.za/what-we-do/mobile-services-tutu/>. Accessed 16 May 2020.
35. Kuhfeld WF. *Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques*. Cary: SAS Institute Inc; 2005. Available from: <https://www.scribd.com/document/52395109/Marketing-Research-Methods-In-Sas>.
36. Minnis AM, Atujuna M, Browne EN, Ndwiyana S, Hartmann M, Sindelo S, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP) for HIV prevention among south African youth: results of a discrete choice experiment. *J Int AIDS Soc*. 2020;23(6):e25528. <https://doi.org/10.1002/jia2.25528>.
37. Test Positive Awareness Network. *Truvada for PrEP (HIV prevention)*. 2016. <https://www.thebodypro.com/article/truvada-for-prep-hiv-prevention>. Accessed 01 July 2020.
38. Avrett S. Can PrEP on Demand for HIV Prevention Work in the U.S.? Experts Answer Your Questions. 2018. <https://www.thebodypro.com/article/can-prep-on-demand-for-hiv-prevention-work-in-the-> Accessed 01 July 2020.
39. PNGImage. Free Tag Icon. 2020. <https://pngimage.net/free-tag-icon-png-8/>. Accessed 01 July 2020.
40. PNGImage. Cash Clipart. 2020. <https://pngimage.net/cash-clipart-png-3/>. Accessed 01 July 2020.
41. VectorStock. Face palm emoticon vector image. 2020. <https://www.vectorstock.com/royalty-free-vector/face-palm-emoticon-vector-12786472>. Accessed 01 July 2020.
42. Clipart Library. Collection of itchy cliparts. 2018. <http://clipart-library.com/itchy-cliparts.html>. Accessed 01 July 2020.
43. Terris-Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much demand for new HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. *PLoS One*. 2013; 8(12):e83193. <https://doi.org/10.1371/journal.pone.0083193>.
44. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. *PLoS One*. 2012;7(1):e28238. <https://doi.org/10.1371/journal.pone.0028238>.
45. Celum C, Hallett TB, Baeten JM. HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness, and public health impact. *J Infect Dis*. 2013;208(2):189–91. <https://doi.org/10.1093/infdis/jit154>.
46. Conroy AA, McGrath N, van Rooyen H, Hosegood V, Johnson MO, Fritz K, et al. Power and the association with relationship quality in South African couples: Implications for HIV/AIDS interventions. *Social Sci Med (1982)*. 2016; 153:1–11. <https://doi.org/10.1016/j.socscimed.2016.01.035>.
47. Roberts ST, Heffron R, Ngunjiri K, Celum C, Kurth A, Curran K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. *AIDS Behav*. 2014;18(9):1701–11. <https://doi.org/10.1007/s10461-014-0804-1>.
48. Skinner D, Mfecane S. Stigma, discrimination and the implications for people living with HIV/AIDS in South Africa. *SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance*. 2004;1(3):157–64. <https://doi.org/10.1080/17290376.2004.9724838>.
49. Treves-Kagan S, El Ayadi AM, Pettifor A, MacPhail C, Twine R, Maman S, et al. Gender, HIV testing and stigma: the association of HIV testing behaviors and community-level and individual-level stigma in rural South Africa differ for men and women. *AIDS Behav*. 2017;21(9):2579–88. <https://doi.org/10.1007/s10461-016-1671-8>.
50. Nkosi B, Seeley J, Ngwenya N, McHunu SL, Gumede D, Ferguson J, et al. Exploring adolescents and young people's candidacy for utilising health services in a rural district, South Africa. *BMC Health Serv Res*. 2019;19(1):195. <https://doi.org/10.1186/s12913-019-3960-1>.
51. Wood K, Jewkes R. Blood blockages and scolding nurses: barriers to adolescent contraceptive use in South Africa. *Reprod Health Matters*. 2006; 14(27):109–18. [https://doi.org/10.1016/s0968-8080\(06\)27231-8](https://doi.org/10.1016/s0968-8080(06)27231-8).
52. Hodges-Mameletzi I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-exposure prophylaxis for HIV prevention in women: current status and future directions. *Drugs*. 2019;79(12):1263–76. <https://doi.org/10.1007/s40265-019-01143-8>.
53. Laher F, Salami T, Hornschuh S, et al. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important. *BMC Public Health*. 2020;20:1669. <https://doi.org/10.1186/s12889-020-09785-0>.
54. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. *Health Econ*. 2012;21(2):145–72. <https://doi.org/10.1002/hec.1697>.
55. Mangham LJ, Hanson K, McPake B. How to do (or not to do) ... Designing a discrete choice experiment for application in a low-income country. *Health Policy Plan*. 2009;24(2):151–8. <https://doi.org/10.1093/heapol/czn047>.
56. Dunne T, Bishop L, Avery S, Darcy S. A review of effective youth engagement strategies for mental health and substance use interventions. *J Adolesc Health*. 2017;60(5):487–512. <https://doi.org/10.1016/j.jadohealth.2016.11.019>.
57. Reed SJ, Miller RL. The benefits of youth engagement in HIV-preventive structural change interventions. *Youth Soc*. 2014;46(4):529–47. <https://doi.org/10.1177/0044118x12443372>.
58. Bailey JL, Molino ST, Vega AD, Badowski M. A review of HIV pre-exposure prophylaxis: the female perspective. *Infect Dis Ther*. 2017;6(3):363–82. <https://doi.org/10.1007/s40121-017-0159-9>.

59. Gill K, Pidwell T, Dietrich J, Gray G, Bennie T, Kayamba F, et al., A demonstration open label study to assess the acceptability, safety and use of Truvada pre-exposure prophylaxis in healthy, HIV-uninfected adolescents, 15–19 years of age. 9th IAS Conference on HIV Science; 2017.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)



## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)